Should transjugular intrahepatic portosystemic shunt be first-line therapy for preventing esophageal variceal rebleeding? A meta-analysis of clinical outcomes

经颈静脉肝内门体分流术是否应作为预防食管静脉曲张再出血的一线治疗方案?一项临床结果的荟萃分析

阅读:1

Abstract

INTRODUCTION: According to Baveno VII guidelines, endoscopic band ligation (EBL) plus nonselective beta-blockers (NSBB) is first-line therapy for preventing esophageal variceal rebleeding, with transjugular intrahepatic portosystemic shunt (TIPS) being used in cases of treatment failure. Our study aimed to compare TIPS with EBL plus NSBB in terms of overall mortality and rate of variceal rebleeding. METHODS: We conducted a comprehensive search on Medline, Google Scholar, Embase, and the Cochrane Library up to January 25, 2025. Randomized control trials (RCTs) comparing TIPS with EBL plus NSBB for variceal bleeding were included in the study. RESULTS: Eight RCTs with 629 patients, 336 receiving TIPS and 293 receiving EBL + NSBB, were included. TIPS had significantly lower rates of variceal rebleeding (odds ratio 0.30, 95% confidence interval 0.19-0.49, P < 0.00001), all-cause rebleeding (P < 0.0001), total episodes of rebleeding (P < 0.0001), new/worsening ascites (P < 0.0001), and peritonitis (P = 0.01). No significant differences were found in mortality, sepsis/pneumonia, hepatic encephalopathy, or hepatocellular carcinoma. CONCLUSION: TIPS offers significant advantages over EBL plus NSBB in reducing variceal rebleeding and other complications but does not improve mortality. Further high-powered trials are needed to refine management strategies for variceal rebleeding in cirrhotic patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。